Whats new

Press releases.

Press releases

January 8th 2020

Immutep Expands Part C of TACTI-002 due to Positive Data

December 18th 2019

INSIGHT-004 Clinical Trial Update

November 13th 2019

Immutep Announces European Patent Grant for LAG525 Antibody

November 7th 2019

Immutep Presents Positive Interim Data from Phase II TACTI-002 Trial at SITC

November 1st 2019

IMMUTEP AGM 2019 - Chairman's Address

November 1st 2019

IMMUTEP AGM 2019 - CEO Marc Voigt's CEO Presentation

November 1st 2019

Update - Consolidation Split - IMM

October 28th 2019

Operational Update

October 15th 2019

Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma

October 10th 2019

Immutep Announces Data Presentations at Upcoming Industry Conferences

October 10th 2019

Immutep Receives A$2.5 Million R&D Tax Incentive from French Government

September 26th 2019

Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data

September 23rd 2019

Immutep to Receive £4M Milestone Payment from GSK

September 17th 2019

Immutep Announces Japanese Patent Grant for LAG525 Antibody

August 22nd 2019

Immutep Granted European Patent for Eftilagimod Alpha in Cancer

August 6th 2019

Immutep Completes A$6M Entitlement Offer

July 29th 2019

Operational Update

June 25th 2019

Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer

June 21st 2019

Immutep Announces Australian Patent Granted for Eftilagimod Alpha in Chemo-Immunotherapy

June 13th 2019

Immutep Completes Recruitment of Initial Cohort in 1st Line NSCLC Patients for TACTI-002 Trial

June 6th 2019

INSIGHT: First Patient Dosed in the 4th arm called “INSIGHT-004”

June 3rd 2019

Immutep Presentation at ASCO 2019

May 23rd 2019

Immutep Announces European Patent Grant for Eftilagimod Alpha in Chemo-Immunotherapy

May 17th 2019

Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma

May 10th 2019

Immutep Announces Upcoming Industry Conference Participation

April 30th 2019

Operational Update

March 27th 2019

Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast

March 25th 2019

Presentation related to webcast 25. March 2019 - Immutep to Present IMP761 Preclinical Results

March 21st 2019

Immutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer

March 18th 2019

Immutep to Present IMP761 Preclinical Results in Global Webcast

March 7th 2019

Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohn’s and Colitis Organisation

March 7th 2019

Immutep receives A$872,351 R&D Tax Incentive

March 6th 2019

Immutep doses First Patient in TACTI-002 Phase II Trial

March 5th 2019

Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma

March 4th 2019

Immutep to Present at Oppenheimer’s 29th Annual Healthcare Conference

February 26th 2019

Immutep to Present at Upcoming Industry Conferences

January 7th 2019

Immutep Enters into Clinical Trial Collaboration, Service and Supply Agreement with Cytlimic

December 19th 2018

Immutep Announces US$5.2 Million Financing Led by U.S. Specialist Healthcare Investor, Altium Capital

November 29th 2018

Immutep Secures European Patent for Eftilagimod Alpha in Combination with Therapeutic Antibodies for Treating Cancer

November 28th 2018

Immutep Granted European Patent for Eftilagimod Alpha in Combination with a PD-1 or PD-L1 Inhibitor

November 27th 2018

New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented at the 4th Annual ICI Europe Summit

November 16th 2018

Annual General Meeting CEO Presentation

November 16th 2018

Chairman’s Address 2018 Annual General Meeting

November 16th 2018

Results of Annual General Meeting

November 12th 2018

Immutep Presents Positive New Data from Ongoing TACTI-mel Study at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

November 1st 2018

Operational Update

October 24th 2018

Immutep Announces Data Presentations at Upcoming Industry Conferences

October 12th 2018

Notice of Annual General Meeting/Proxy Form

October 2nd 2018

Immutep Announces Presentations at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

September 26th 2018

Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference

September 24th 2018

Immutep Enters into Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer

September 3rd 2018

Progress Towards Clinical Development of IMP761 - A LAG-3 Agonist Antibody

August 21st 2018

Immutep Receives A$1.9 Million Research and Development Related Tax Rebate from French Government

August 16th 2018

Immutep to Present at the BioCentury 25th Annual NewsMakers in the Biotech Industry Conference

August 7th 2018

Immutep Secures Canadian Patent Grant for IMP731 Antibody

August 7th 2018

TACTI-mel Patient Recruitment Complete and Operational Update

July 31st 2018

Immutep's LAG-3 Immunostimulant Product Candidate, Efti, Receives IND Approval from U.S. FDA

July 2nd 2018

Immutep Submits Investigational New Drug (IND) Application with FDA

June 19th 2018

Mid-Point of Patient Enrolment Reached in AIPAC Trial

June 4th 2018

Immutep Presentations at ASCO

May 30th 2018

Positive New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented in Global Webcast

May 17th 2018

Immutep to Present Interim Results from TACTI-mel Clinical Trial in Global Webcast

May 4th 2018

Immutep to Present at 2018 ASCO Annual Meeting

April 13th 2018

Immutep Completes $6.31 Million Share Purchase Plan; Raises Total of $13.16 Million

April 3rd 2018

Operational Update

March 22nd 2018

Updated TACTI-mel Data presented at the Cambridge Healthtech Institute’s Immuno-Oncology Summit

March 22nd 2018

Immutep Commences Patient Dosing In Additional TACTI-mel Cohort

March 13th 2018

Share Purchase Plan Offer Document

March 12th 2018

Immutep Enters Into Clinical Trial Collaboration and Supply Agreement with MSD

March 11th 2018

Immutep Raises A$6.85M Through Institutional Placement

March 6th 2018

Immutep Announces United States Patent Grant for IMP701 Antibody

March 5th 2018

Immutep receives A$686,704 R&D Tax Incentive

February 9th 2018

Outcome from DSMB Safety Review and Extension of TACTI-mel Phase I Clinical Trial

February 1st 2018

Immutep Limited Announces Milestone Payment from Chinese Partner EOC Pharma

December 12th 2017

Operational Update

November 28th 2017

Prima BioMed Becomes Immutep

November 22nd 2017

Prima Secures European Patent Grant for Lead Product IMP321 in Cancer

November 20th 2017

Prima BioMed Changes its Name to Immutep Ltd

November 20th 2017

FAQ - Change of company name from 'Prima BioMed Limited' to 'Immutep Limited'

November 17th 2017

Chairman’s Address 2017 Annual General Meeting

November 17th 2017

Results of Annual General Meeting

November 17th 2017

Annual General Meeting CEO Presentation

November 15th 2017

Eftilagimod Alpha (LAG-3Ig or IMP321) Pre-IND Meeting with the FDA

November 9th 2017

New Eftilagimod Alpha (LAG-3Ig or IMP321) Data for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting

November 1st 2017

Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017

October 20th 2017

Dr. Frédéric Triebel presenting at the World Immunotherapy Congress 2017

October 17th 2017

Notice of Annual General Meeting/Proxy Form

October 17th 2017

IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting

September 8th 2017

Prima Secures Japanese Patent Grant for IMP731 Antibody

September 5th 2017

Prima Secures Japanese Patent Grant for Lead Product IMP321 in Infectious Disease

August 30th 2017

Prima BioMed and Monash University Receive Funding Grant for LAG-3 Research Project

August 21st 2017

Prima BioMed Appoints Non-Executive Director to the Board

August 21st 2017

Appendix 3X

August 7th 2017

Appendix 3B

August 7th 2017

Appendix 3Y

August 6th 2017

Prima BioMed Receives A$1.3 Million Tax Refund from French Government

July 18th 2017

Financial Update 2H17

July 17th 2017

Prima BioMed Announces Second Milestone Payment for IMP701 Program

July 10th 2017

Prima BioMed Announces Approval for the Initiation of the ‘INSIGHT’ Clinical Trial

July 6th 2017

Disclosure Under Listing Rules 3.10.5A and 7.1A.4(b)

July 6th 2017

Cleansing Notice

July 4th 2017

Appendix 3B – US$5m Capital Raising

July 3rd 2017

Final Prospectus Supplement

June 30th 2017

Prima BioMed Announces Pricing of US$5.0 Million Registered Direct Offering of Its American Depositary Shares

June 26th 2017

Operational Update

June 5th 2017

LAG-3Ig (IMP321) demonstrates positive Safety and Efficacy Qualities in Breast Cancer Clinical Trial

June 5th 2017

ASCO Poster 2017

June 1st 2017

Prima BioMed Announces Formation of Clinical Advisory Board

May 18th 2017

Data from Prima BioMed AIPAC Clinical Trial to be Presented at 2017 ASCO Conference

April 19th 2017

Prima BioMed Receives Approval for Third Cohort of Phase I Melanoma Trial

April 12th 2017

Prima BioMed receives A$492,144 Tax Refund from Australian Government

March 15th 2017

Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston

March 1st 2017

USA Patent Grants for IMP321 in Cancer

February 24th 2017

First Half 2017 Operational Update

February 13th 2017

Prima BioMed Receives ~A$860,000 Tax Credit Payment from French Government

January 23rd 2017

Prima BioMed to Present at 2nd Annual Cancer Immunotherapy Conference

January 20th 2017

Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer

January 18th 2017

Prima BioMed to Maintain NASDAQ Listing

January 12th 2017

Prima BioMed Commences Recruitment for Second Cohort of Melanoma Trial

January 5th 2017

Prima BioMed enters new Material Transfer Agreement with Cytlimic

January 2nd 2017

Prima announces new Product Candidate IMP761 – a LAG-3 Agonist Antibody

December 29th 2016

PRIMA BIOMED ANNOUNCES FIRST CLINICAL DATA FROM COMBINATION OF IMP321 WITH ANTI-PD1

December 22nd 2016

PRIMA BIOMED ANNOUNCES DATA FROM IMP321 AIPAC CLINICAL TRIAL IN BREAST CANCER

December 5th 2016

PRIMA BIOMED ENTERS INTO SALE AND LICENSING AGREEMENT WITH SYDYS TO ADVANCE CVAC™ PROGRAM

October 13th 2016

PRIMA TO PRESENT AT 2016 SOCIETY FOR IMMUNOTHERAPY OF CANCER CONFERENCE

October 6th 2016

PRIMA ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT ESMO SYMPOSIUM ON IMMUNO-ONCOLOGY

August 18th 2016

Operational Update

August 10th 2016

PRIMA BIOMED RECEIVES NASDAQ NOTICE OF BID PRICE DEFICIENCY

July 12th 2016

PRIMA BIOMED COLLABORATES IN INVESTIGATOR SPONSORED NEW CLINICAL TRIAL FOR IMP321 IN SOLID TUMORS

July 6th 2016

PRIMA BIOMED TO MAINTAIN NASDAQ LISTING

June 22nd 2016

PRIMA BIOMED ANNOUNCES FIRST SAFETY, PHARMACOKINETICS AND IMMUNO-MONITORING DATA FROM PHASE IIB CLINICAL TRIAL OF IMP321

March 15th 2016

IMP321 SAFETY AND IMMUNE MONITORING DATA PUBLISHED IN CLINICAL CANCER RESEARCH JOURNAL

March 4th 2016

PRIMA BIOMED RECEIVES NASDAQ NOTICE OF BID PRICE DEFICIENCY

March 2nd 2016

Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologic in EU Clinical Trial

February 5th 2016

JAPANESE PATENT GRANTS FOR IMP321 IN CANCER

January 28th 2016

US PATENT GRANTS FOR IMP731 ANTIBODY

January 27th 2016

PRIMA BIOMED INITIATES PHASE I MELANOMA STUDY IN AUSTRALIA

December 22nd 2015

PRIMA BIOMED INITIATES PHASE IIB STUDY IN METASTATIC BREAST CANCER

December 11th 2015

PRIMA BIOMED PROGRESSES JAPANESE COLLABORATION

November 26th 2015

PRIMA BIOMED RECEIVES TAX REBATE FROM AUSTRALIAN GOVERNMENT

November 18th 2015

PRIMA BIOMED UNVEILS PHASE I COMBINATION STUDY OF IMP321 + CHECKPOINT INHIBITOR

November 5th 2015

PRIMA BIOMED WILL PRESENT AT THE ICI EUROPE MEETING IN GERMANY, NOVEMBER 16-18, 2015

October 27th 2015

PRIMA BIOMED GAINS BELGIAN REGULATORY APPROVAL TO COMMENCE A REGISTRATION PHASE IIB STUDY OF IMP321

October 13th 2015

PRIMA BIOMED RAISES A$1.55M THROUGH PLACEMENT TO SOPHISTICATED EUROPEAN HEALTHCARE INVESTOR

October 9th 2015

PRIMA BIOMED RECEIVES GRANT FROM THE SAXONY DEVELOPMENT BANK

September 25th 2015

PRIMA BIOMED TO PRESENT AT LEERINK PARTNERS RARE DISEASE ROUNDTABLE

August 14th 2015

PRIMA BIOMED ANNOUNCES COMMENCEMENT OF MILESTONES FOR IMP701 PROGRAM

August 4th 2015

PRIMA BIOMED TERMINATES INVESTMENT FACILITY WITH BERGEN GLOBAL OPPORTUNITY FUND, LP

August 1st 2015

Re: Results of 2015 Extraordinary General Meeting

July 31st 2015

Prima Biomed Ltd 2015 Extraordinary General Meeting

July 24th 2015

PRIMA BIOMED RAISES A$10M THROUGH SHARE PURCHASE PLAN

July 10th 2015

SHARE PURCHASE PLAN OFFER DOCUMENTS

July 7th 2015

PRIMA BIOMED RECEIVES POSITIVE SCIENTIFIC ADVICE FROM THE EUROPEAN MEDICINES AGENCY FOR ITS LEAD PRODUCT, IMP321

June 29th 2015

A MESSAGE FROM THE CHAIRMAN

June 11th 2015

PRIMA BIOMED RECEIVES A RESEARCH TAX CREDIT CASH REBATE IN FRANCE

June 4th 2015

PRIMA BIOMED TO MAINTAIN NASDAQ LISTING

May 29th 2015

PRIMA BIOMED ANNOUNCES NEW IP FOR ITS LEAD IMP321 DEVELOPMENT PROGRAM

May 25th 2015

PRIMA BIOMED TO COMMERCIALISE CVAC’S DATABASE MANAGEMENT PLATFORM WITH DATABASE INTEGRATIONS INC. (DBI)

May 19th 2015

CVAC SHOWS OVERALL SURVIVAL BENEFIT IN SECOND REMISSION OVARIAN CANCER IN PHASE II STUDY

May 14th 2015

PRIMA BIOMED ANNOUNCES A$15 MILLION INVESTMENT FROM US HEALTHCARE INVESTOR RIDGEBACK

May 11th 2015

PRIMA BIOMED ANNOUNCES JAPANESE COLLABORATION

April 29th 2015

PRIMA BIOMED TO PRESENT AT CANARY NETWORKS’ BIOTECH AND HEALTHCARE INVESTOR ROADSHOW

February 27th 2015

PRIMA BIOMED PRIORITISING IMP321

January 27th 2015

FINANCIAL MILESTONE PAYMENT TO BE RECEIVED FROM GSK

January 20th 2015

$777K R&D TAX INCENTIVE REFUND RECEIVED

January 20th 2015